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Summary: In TB meningitis, higher pre-treatment CSF bacterial load increased disease severity 
and host inflammation. Bacterial load can be used to predict new neurological events but not 
death. Reducing neurological complications and deaths may need reassessment due to their 
divergent pathogenesis.  
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Abstract 
Background: Mycobacterium tuberculosis (Mtb) bacillary load in the brain of those with 
tuberculous meningitis (TBM) may reflect the host ability to control the pathogen and determine 
disease severity and treatment outcomes.  
Methods: We measured pre-treatment cerebrospinal fluid (CSF) Mtb bacterial load by 
GeneXpert in 692 adults with TBM. We sought to understand the relationship between CSF 
bacterial load and inflammation, and their respective impact on disease severity and treatment 
outcomes.  
Results: Ten-fold higher Mtb load was associated with increased disease severity (Odds 
Ratio=1.59, p=0.001 for grade 1 versus grade 3), and increased CSF neutrophils (r=0.364, 
p<0.0001) and cytokine concentrations (r=0.438, p<0.0001). High Mtb load predicted new 
neurological events after starting treatment (Multinomial logistic regression, p=0.005), but not 
death.  Death was previously associated with attenuated inflammatory response at the start of 
treatment, with reduced cytokine concentrations compared to survivors. In contrast, patients with 
high pre-treatment CSF bacterial loads, cytokines, and neutrophils were more likely to 
subsequently suffer neurological events.  
Conclusions: Pre-treatment GeneXpert-derived Mtb load may be a useful predictor of 
neurological complications occurring during TBM treatment. Therapeutic strategies aimed at 
reducing neurological complications and deaths from TBM may need reassessment, given the 
evidence for their divergent pathogenesis. 
 
Key words: bacterial load, tuberculous meningitis, inflammatory response, cytokines, 
neurological events
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Introduction 
Tuberculous meningitis (TBM) is the most severe form of tuberculosis (TB). It is caused by 
dissemination of Mycobacterium tuberculosis (Mtb) to the brain, resulting in meningo-
encephalitis with necrotising, granulomatous inflammation predominantly affecting the basal 
meninges. Inflammation can lead to life-threatening complications of hydrocephalus, infarcts and 
tuberculomas (1, 2). Death or neurological disability still occur in half of all cases.  
The pathogenesis of TBM is not well understood. Much of the pathology is thought to arise from 
the immune response to replicating bacteria, but the nature of that response and its relationship to 
bacterial numbers is presently poorly defined (3). Recent studies in large, well-characterised 
cohorts of HIV-uninfected Vietnamese adults with TBM demonstrated that elevated 
cerebrospinal fluid (CSF) cytokine concentrations in 8/10 tested cytokines were associated with 
more severe disease (4). Death, however, was associated with an attenuated inflammatory 
response, with lower CSF cytokine concentrations and leukocyte counts (4), and with higher 
CSF neutrophil counts (5). HIV infection, and polymorphism rs17525495 in the gene encoding 
leukotriene A4 hydrolase (LTA4H), influenced both pretreatment CSF inflammatory phenotype 
and survival from TBM in Vietnamese individuals (4), but the polymorphism was not associated 
with survival in Indon sians (5). 
Neutrophils appear to play an important role in TBM pathogenesis (5). Higher CSF neutrophil 
numbers have been associated with an increased likelihood of culturing Mtb from the CSF (6, 7) 
and cerebral immune reconstitution inflammatory syndrome (IRIS) in those co-infected with 
HIV (8, 9). 
One of the fundamental questions concerning TBM pathophysiology is how Mtb bacterial load 
relates to intracerebral inflammation and outcome. Very low bacterial numbers in CSF, and 
inadequate laboratory methods, have to date made this question largely refractory to 
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investigation. CSF culture positivity may indicate higher bacterial loads,  and was associated 
with mortality in HIV-uninfected TBM patients (5). More recent molecular assays, such as 
GeneXpert, quantify the presence of bacterial nucleic acid in CSF and are now widely used for 
TBM diagnosis. Although GeneXpert’s sensitivity for TBM diagnosis is around 60% compared 
to clinical diagnosis (12), when positive it categorizes CSF bacterial load as very low, low, 
medium, or high, thus offering a new way to assess CSF Mtb load in clinical practice. The aim of 
our study was to use GeneXpert to define CSF bacterial load in a large cohort of well-
characterised Vietnamese adults with TBM; and to investigate the relationship between bacterial 
load and CSF cytokine concentrations, leucocyte numbers and types, and the occurrence of new 
neurological events and death after the start of anti-tuberculosis treatment.    
Methods 
Participants 
Adults (>17 years) with TBM were enrolled into a randomized controlled trial of intensified anti-
tuberculosis chemotherapy between April 2011 and June 2014 (10). Of the 817 trial participants, 
692 had CSF GeneXpert data and were included in the current study. The other 125 participants 
had missing data due to insufficient volume of CSF samples or GeneXpert test errors. 
Written informed consent was obtained from each participant or from an accompanying relative 
if the participant could not provide consent. Protocols were approved by the Oxford Tropical 
Research Ethics Committee in the United Kingdom, the institutional review boards of the 
Hospital for Tropical Diseases and Pham Ngoc Thach Hospital for Tuberculosis and Lung 
Disease, and the Ethical Committee of the Ministry of Health in Vietnam. 
Treatment 
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Participants were randomly allocated to treatment with (a) standard anti-tuberculosis regimen for 
3 months, followed by rifampicin and isoniazid at the same doses for a further 6 months, or (b) 
an intensified regimen that consisted of the standard regimen with an additional higher dose of 
rifampicin (15 mg/kg/day) and levofloxacin (20 mg/kg/day) for the first 8 weeks of treatment. 
All participants also received adjunctive dexamethasone for the first 6–8 weeks of treatment 
(10). 
Clinical and CSF characteristics  
We extracted data on participant age, weight, duration of illness (days of symptoms), Glasgow 
coma score (GCS), British Medical Research Council (BMRC) grading for TBM, TB treatment 
and HIV status on the date of TBM diagnosis. All participants were followed for 9 months, with 
careful characterization of their clinical response to treatment. New neurological events were 
defined as the new occurrence of any of the following: cerebellar symptoms, mono-, hemi-, para, 
or tetraplegia, seizures, cranial nerve palsy, or a fall in GCS by ≥ 2 points for ≥ 2 days from the 
highest previously recorded score (10). These events encompass paradoxical treatment reactions, 
which are thought to be caused by an excessive inflammatory response to dead or dying bacteria 
(11) and death of brain tissue.  
Laboratory data were collected from samples taken on the date of enrollment, including blood 
and CSF cell counts, and cytokine concentrations. A panel of 10 cytokines important in 
inflammation in TB, comprising six pro-inflammatory cytokines (interleukin1β (IL-1β), IL-2, IL-
6, IL-12p70, interferon γ (IFN-γ), and tumor necrosis factor α (TNF-α)) and four anti-
inflammatory cytokines (IL-4, IL-5, IL-6 and IL-13), was measured in stored CSF specimens 
using Luminex multiplex bead-based assay (4). LTA4H rs17525495 polymorphism was 
genotyped by TaqMan genotyping assay (3). 
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GeneXpert MTB/RIF, which detects Mtb complex and rifampicin resistance, was performed on 
CSF before the start of anti-TB treatment (12). Briefly, 3-5 ml of CSF was centrifuged for 20 
minutes at 3000g; 200 μl(about one-third of the deposit) was resuspended in phosphate-buffered 
saline and mixed with 1.5 ml of sample reagent, vortexed for 30 seconds, incubated for 15 
minutes at room temperature then transferred to a GeneXpert cartridge for measurement. The 
GeneXpert Dx software (version 4.0; Cepheid) reported semiquantitative mycobacterial load 
results as cycle threshold (Ct) values, representing the number of PCR cycles required for the 
signal to reach a detection threshold. Mtb loads were classified as high (Ct <16), medium (Ct 16-
22), low (Ct 22-28), and very low (Ct >28). Mycobacterium bovis (BCG, NCTC 5692) was used 
to generate a standard curve of GeneXpert Ct values versus bacterial number by the Miles and 
Misra method (13). For each sample, the average Ct value of five probes (excluding any delayed 
values due to rifampicin resistance) was used to estimate bacterial load and analyse further.  
Statistical Analysis 
Data were analysed using statistical package R v3.0.1 (14), MATLAB and Statistics Toolbox 
Release 2013a (The MathWorks Inc., Natick, Massachusetts, USA), and Graphpad Prism version 
6 (Graphpad Software Inc., San Diego, California, USA). In statistical analyses, to preserve the 
statistical power we used continuous comparisons of the whole dataset, with GeneXpert negative 
assigned a Ct value of 40; meanwhile most of the graphical representations use bacterial load in 
categories for clarity.  
Baseline concentrations of the ten CSF cytokines were analysed using principal component 
analysis (PCA), a method of transforming complex correlated datasets into a new coordinator 
system (component space) in which two or three first principle components can cover up to 70% 
- 80% variance of the whole dataset. By this means we visualized our multi-variate dataset and 
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avoided multiple comparisons (15, 16). Associations between Mtb load and cytokine principal 
components (PCs), blood or CSF cell counts were examined using Spearman rank correlation 
coefficient, in which log-transformed cell counts were used to analyse correlations. Comparisons 
of bacterial loads by GCS or disease severity, CSF neutrophils and cytokines were performed by 
a linear trend test implemented using robust linear regression. We classified outcomes into three 
groups: (1) ‘survival’ means participants survived without new neurological events, (2) ‘new 
neurological events’ means they survived with new neurological events occurring during 
treatment and (3) ‘death’ means they died during treatment. Comparisons of bacterial load 
between survival and new neurological events or death utilized Mann-Whitney tests. The 
outcome was modeled using multinomial logistic regression depending on Mtb bacterial load and 
the detection limit indicator. The model was later adjusted for predefined risk factors including 
age, weight, GCS, CSF leukocyte numbers, anti-tuberculosis regimen, anti-retroviral therapy, 
HIV infection, and LTA4H genotype. Separate analysis was also performed for each HIV status. 
We used the Hochberg method to correct p-values for multiple testing. 
 
Results 
Characteristics of the participants 
The baseline clinical characteristics of the 692 TBM adults with CSF Mtb load assessed by 
GeneXpert are described in Table 1.  293 (42.3%) were GeneXpert positive and these were 
significantly more likely than the GeneXpert negative participants to be HIV-infected and to 
have more severe disease. The majority of participants (568, 82.1%) had BMRC grade 1 or 2 
disease at enrollment. The detection of Mtb in CSF by microscopy and MGIT culture were 257 
(37.6%) and 281 (41.2%). In the 228 patients positive in both GeneXpert and MGIT culture, 
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correlation between the bacillary load and the days to culture positivity was 0.417, p<0.0001. 
Participants who were GeneXpert positive had higher numbers of leucocytes, percentage of 
neutrophils, and levels of protein and lactate in CSF than those who were GeneXpert negative. 
Clinical characteristics of HIV-uninfected and -infected patients and their blood and CSF 
parameters are shown in Table S1. 
Positive detection of Mtb by GeneXpert in HIV-infected participants (165/288, 57.3%) was 
higher than in HIV-uninfected participants (128/404, 31.7%) (p<0.0001), although Mtb loads in 
these two groups were not significantly different (p=0.087). Pre-treatment GeneXpert CSF 
bacterial loads varied from very low to medium; a high load was not recorded. In the 404 HIV-
uninfected participants, 276 (68.3%) had a negative test, 63 had very low bacterial loads 
(15.6%), 58 low loads (14.4%), and 7 medium loads (1.7%). In the 288 HIV-infected 
participants, 123 (42.7%) had a negative test, 72 had very low bacterial loads (25.0%), 74 low 
loads (25.7%), and 19 medium loads (6.6%) (Figure 1). Conversions from Ct value to bacterial 
number, and ranges of bacterial number by levels of bacterial load, can be found in Figure S1. 
 
 
Association between pre-treatment Mtb load and disease severity  
The associations between Mtb load and GCS or BMRC grade were examined before treatment in 
692 TBM adults. Mtb loads  showed positive correlations with GCS (Spearman correlation: HIV-
uninfected, r= 0.194, p < 0.0001; HIV-infected, r= 0.238, p< 0.0001) , i.e. higher bacterial loads 
in those with more severe coma, and increased Mtb load was associated with lower GCS (linear 
trend test: HIV-uninfected, p= 0.0004; HIV-infected, p< 0.0001; Figure 2A).  
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In addition, increased Mtb load was also associated with more severe disease assessed by BMRC 
grade (linear trend : HIV-uninfected, p= 0.008; HIV-infected, p= 0.001). Bacterial load (per 10-
fold increase) affected disease severity in all participants [grade 1 vs. grade 2, odds ratio (OR) 
0.71, 95% confidence interval (CI) 0.91-1.50, p= 0.226; grade 1 vs. grade 3, OR 1.59, 95% CI 
1.19-2.15, p= 0.001]; in HIV-uninfected participants (grade 1 vs. grade 2, OR 1.56, 95%  CI 
1.02-2.47, p= 0.039; grade 1 vs. grade 3, OR 1.84, 95% CI 1.12-3.21, p= 0.015), and in HIV-
infected participants (grade 1 vs. grade 2, OR 1.0, 95% CI 0.7-1.4, p= 0.878; grade 1 vs. grade 3, 
OR 1.5, 95% CI 1.1-2.2, p= 0.013). The duration of illness before treatment was not associated 
with BMRC grade (p= 0.977) or Mtb load (p= 0.651). 
Correlations between pre-treatment CSF Mtb load and inflammation 
To investigate whether Mtb load before treatment was related to inflammatory responses we first 
explored the relationship between Mtb load and blood and CSF cell counts. Bacterial load by Ct 
values showed negative correlations with neutrophil numbers in blood and CSF in both HIV-
infected and uninfected participants (Table 2, Figure 2B). These correlations were stronger in 
CSF (r = -0.395, p < 0.0001, Figure S3) than in blood (Table 2), suggesting that neutrophil 
recruitment correlated more strongly with bacterial replication at the infected site. 
PCA was applied to ten baseline CSF cytokines to identify correlated measurements that account 
for the variance of the data set. The first component, PC1, covered 71.4% variance of the 
cytokine profile, PC2 covered 6.4%, PC3 4.9%, PC4 4.4% and other components covered less 
(Figure S2). In other words, the majority of the variance was reflected by just the two first 
principal components (PC1 and PC2). Because all the coefficients were located in quadrant I and 
quadrant IV, a positive value of PC1 implies high concentration across all cytokines. In other 
words, these cytokines were in strong co-correlation with each other. Meanwhile the PC2 
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explains the difference in cytokine concentrations of two groups: IL-13, IFN-γ, IL-10, IL-5 
versus  IL-2, IL-6, IL-1β. We used the first two components to represent the cytokine profile to 
assess whether bacterial load was related to cytokine concentrations. Mtb load by Ct values 
showed a negative relationship with PC1 overall (r = -0.493, p < 0.0001) and in participants 
stratified by HIV infection (p < 0.0001, r = -0.448 and -0.487 for HIV-uninfected and infected 
respectively, Table 2). Mtb loads were not correlated with PC2 in participants stratified by HIV. 
These results suggest that participants with high Mtb load tended to have high concentrations of 
measured cytokines. This can be seen particularly in the strong relationship between Mtb load 
and the key pro-inflammatory cytokines IL-1β and TNF-α (Table 2, Figure 2 C, D, Figure S3). 
Interestingly, CSF neutrophil count was positively correlated with PC1 regardless of HIV 
infection (all TBM, r= 0.381, p< 0.0001; HIV-uninfected, r= 0.385, p< 0.0001; HIV-infected, r= 
0.317, p= 0.0003). 
Association between LTA4H genotype and Mtb load 
Previously, we showed that in HIV-uninfected adults with TBM, LTA4H genotype was 
associated with CSF IL-1β, IL-2, and IL-6 concentrations, with low concentrations in genotype 
CC, intermediate concentrations in CT, and high concentrations in TT (4). Laarhoven et al. 
reported that TT genotype was associated with decreased CSF culture positivity (5). We analysed 
the relationship of LTA4H genotype and bacterial load, and found Mtb load in participants with 
TT-genotype was slightly lower than that in CC (p = 0.051) or CT (p = 0.015), however the 
linear trend test showed LTA4H genotype was not associated with Mtb load overall (p = 0.302, 
Figure S4).  
Relationship between CSF Mtb load, inflammation, and new neurological events  
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/advance-article-abstract/doi/10.1093/infdis/jiy588/5123684 by guest on 19 O
ctober 2018
Ac
ce
pte
d M
an
us
cri
pt
 
 
Study participants were treated with intensive (n=347) or standard anti-TB treatment (n=345). As 
previously reported, the intensive regimen was not associated with any improvement in any 
measure of treatment response or outcomes, including survival (10). During 9 months of anti-
tuberculosis treatment, new neurological events developed in 103 participants (14.9%), the 
median time to new events after the start of treatment was 9 days (IQR 3-43) (Figure S5A). 
New neurological events were significantly associated with higher pre-treatment Mtb loads in the 
GeneXpert positive dataset (p = 0.004 in HIV-uninfected, p = 0.022 in HIV-infected, Figure 3A). 
In the whole dataset, elevated Mtb load increased risk of new neurological events (OR= 1.68, 
95% CI 1.26-2.25 per 10-fold bacterial increase, p= 0.0004, Table 3). In both HIV-uninfected 
and infected participants, these events were also associated with high baseline CSF neutrophil 
counts, high baseline PC1 score and high baseline TNF-α concentrations (Figure 3B, C, D).  
The pathogenesis of neurological events may differ according to their timing during treatment. 
Therefore, we categorized participants by the median time to new neurological events < 9 days 
or ≥ 9 days, and compared bacterial loa  between these two groups. Bacterial loads were not 
significantly different between early and late neurological events (p = 0.196 in HIV-uninfected, p 
= 0.061 in HIV-infected, Figure S6A). 
Predictors of new neurological events 
The results (Table 3) indicated that increased Mtb load was independently associated with new 
neurological events in all participants (OR 1.56, 95% CI 1.14–2.11, p= 0.005 and adjusted p= 
0.045; per 10-fold load increase). Mtb load was significantly associated with new neurological 
events in HIV-uninfected participants (OR 1.97, 95% CI 1.18–3.28, p= 0.009) and with a trend 
in HIV-infected participants (OR 1.43, 95% CI 0.95–2.15, p= 0.082). Results stratified by HIV 
infection lost statistical significance after adjustment for multiple testing. GCS was also strongly 
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associated with new neurological events (OR 0.77, 95% CI 0.71–0.84, p < 0.0001; per point 
increase). These findings highlight that pretreatment CSF Mtb load can be used as a predictor, 
together with GCS, of new neurological events occurring during TBM treatment. 
Relationship between CSF Mtb load, inflammation, and death 
Death occurred in 192 (27.7%) participants, a median of 39 days (IQR 9-103) after the start of 
treatment (Figure S5B). Bacterial load was not significantly associated with death, with or 
without neurological events, in either HIV-uninfected or infected participants in the GeneXpert 
positive dataset (Figure 3A). Although CSF neutrophil counts were similar between those who 
died and survived (Figure 3B), measured cytokine concentrations were significantly lower in 
those who died, with or without neurological events, in HIV-uninfected participants (Figure 3C 
and D) in the whole dataset. To examine whether early death was associated with bacterial load, 
we categorized participants by the median time to death < 39 days or ≥ 39 days. Bacterial loads 
were not significantly different between those dying early or late (HIV-uninfected, p = 0.731; 
HIV-infected, p= 0.099; Figure S6B).    
Taken together, our data showed that high Mtb load was associated with more severe disease at 
baseline and strongly predicted new neurological events after the start of treatment, but did not 
influence 9-month mortality (Table 3). 
Discussion 
TBM is one of the most difficult forms of TB to treat, with outcomes dependent upon killing the 
bacteria with anti-tuberculosis drugs and controlling intracerebral inflammation. However, the 
relationships between bacterial numbers, inflammation, and treatment response are poorly 
defined, primarily because of the difficulties assessing Mtb load at the site of infection. We 
overcame some of these difficulties by quantifying bacterial numbers in CSF by GeneXpert in a 
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large cohort of well-characterized patients recruited to a randomized controlled trial of intensive 
anti-tuberculosis therapy (10). We found that pretreatment CSF Mtb load was associated with 
increased CSF neutrophil numbers, enhanced inflammation and disease severity, and predicted 
the likelihood of new neurological events after the start of anti-TB treatment.  
CSF bacterial load showed significant correlations with neutrophil numbers in blood and CSF in 
both HIV-infected and uninfected participants. Previously, CSF neutrophil numbers have been 
associated with positive CSF Mtb cultures (6, 17) and studies in HIV-coinfected individuals have 
linked the presence of Mtb in the CSF with a neutrophil-mediated inflammatory response and an 
increased risk of intracerebral IRIS (9). Neutrophils may be protective in early Mtb infection 
(18), although animal models suggest they may exacerbate pathology in the later stages of 
disease  (19, 20). Clinical studies in active TB have suggested neutrophils may influence disease 
progression and outcome: higher blood neutrophil counts before treatment have been associated 
with increased risk of mortality in TB patients (of which 49.4% were pulmonary TB) (21) and 
slower sputum conversion to negative during therapy in pulmonary TB (22). In transcriptional 
profiling of blood,  the signature of active TB patients was characterised by a neutrophil-driven 
interferon inducible gene expression (23). Taken together, these findings all suggest that 
neutrophils play an important role in TB pathogenesis.  
Almost half the participants suffered serious clinical complications during treatment (new 
neurological events in 14.9%; death in 27.7%). Surprisingly, we found that CSF Mtb load 
influenced the likelihood of new neurological events, but not mortality, suggesting different 
underlying mechanisms. In support of this assertion, current and previous data suggest new 
neurological events are associated with high concentration of CSF cytokines before the start of 
treatment, whilst death is associated with attenuated inflammatory responses (4). 
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One of the limitations of our study was that we were unable to define the likely cause of the new 
neurological events by brain imaging. However, given the nature and timing of the events, and 
their association with increased inflammation, it is reasonable to assume that many could be 
defined as ‘paradoxical’ treatment reactions (11). Therefore, taken together with the recent 
finding by Marais et al (9), our data provides further evidence for the importance of bacterial 
load and neutrophils in treatment-associated inflammatory complications in HIV-infected and 
uninfected adults with TBM.  Our findings support the hypothesis that the pathogenesis of IRIS 
and paradoxical reactions are similar, resulting from excessive neutrophil-mediated inflammation 
and driven by Mtb load. Drugs with the potential to target neutrophils (e.g. roflumilast, 
ibuprofen, doxycycline (11)) may be more effective than corticosteroids in the treatment of these 
common complications. 
An additional limitation of our study was that we could not follow the decline of bacterial loads 
after the start of treatment. Even before the start of anti-tuberculosis treatment CSF bacillary 
loads are very low. In our participants, pre-treatment bacillary loads in CSF were at least a 
hundred-fold lower  than loads reported in sputum ofpulmonary TB patients(24). Furthermore, 
repeated CSF sampling early in treatment is rarely clinically justifiable, which further restricts 
the information available. We routinely sample CSF after 30 and 60 days of therapy, by which 
time bacterial loads are almost always below the detection threshold.  
In summary, our data shed new light on the pathogenesis of TBM and suggest divergent 
mechanisms that lead to death and neurological events occurring after the start of treatment. 
Death from TBM is associated with an attenuated inflammatory response at the start of 
treatment, with reduced CSF leucocytes and cytokine concentrations compared to survivors. In 
contrast, patients with high pre-treatment CSF bacterial loads, cytokines, and neutrophils are 
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more likely to suffer new neurological events or ‘paradoxical’ inflammatory complications. 
These findings may have important implications for the selection of future host directed 
therapies. 
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Figure legends 
Figure 1. Bacterial load in TBM participants uninfected or infected with HIV before the 
start of anti-tuberculosis treatment 
Percentages of Mtb levels, including not-detected (ND), very low, low and medium, in 404 HIV-
uninfected and 288 HIV-infected patients.   
 
 
Figure 2. Associations between bacterial load and disease severity, CSF neutrophil counts, 
and CSF cytokine concentrations in TBM participants before the start of anti-tuberculosis 
treatment  
GCS, Glasgow coma score; ND, not-detected 
Data are for Mtb levels at baseline in 404 HIV-uninfected patients (276 ND, 63 very low, 58 low 
and 7 medium) and in 288 HIV-infected participants (123 ND, 72 very low, 74 low and 19 
medium). Associations between baseline Mtb levels and (A) GCS (B) CSF neutrophil counts, (C) 
CSF IL-1β and (D) CSF TNF-α; p-values were derived from linear trend test. Long bars in plots 
represent median and short bars were below and/or above inter-quantile range values. 
 
Figure 3. Associations between pre-treatment CSF bacterial load, inflammation, and new 
neurological events or death  
(A) Comparison of the number of bacteria in CSF using the Ct value which is inversely 
proportional to bacterial load (i.e. the lower the value, the higher the load) in survivors [S], those 
with new neurological events [N] and those who died [D] in HIV-infected and HIV-uninfected 
participants. Numbers of cases were presented in brackets. (B) Comparison of numbers of 
neutrophils in CSF at baseline in HIV-infected and HIV-uninfected participants who survived, 
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suffered new neurological events, or died. (C, D) Comparison of CSF cytokine concentrations 
PC1 or TNF-α in HIV-uninfected in HIV-infected participants who survived, suffered new 
neurological events, or died. p
#
, comparison of S vs. D; p
^
, comparison of N vs. D. Bars in plots 
represent median and inter-quantile range values. Statistical comparisons between survival 
versus new neurological events or death were made using Mann-Whitney tests. CSF neutrophil 
and cytokine data were available for 657 and 554 patients respectively. 
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Table 1. Baseline clinical characteristics of all 692 TBM participants by CSF GeneXpert 
Characteristic All 
GeneXpert 
negative 
GeneXpert 
positive 
p 
value
s 
  n 
Summary 
statistic n 
Summary 
statistic n 
Summary 
statistic   
Age (years) – median (IQR) 
69
2 35 (29, 46) 
39
9 36 (29, 50) 
29
3 35 (29, 42) 0.008 
Male sex – no. (%) 
69
2 475 (68.6) 
39
9 
261 (65.4) 
29
3 
214 (73.0) 
0.038 
Weight (kg) – median 
(IQR) 
69
2 48 (44, 54.5) 
39
9 49 (45, 55) 
29
3 48 (43, 54) 0.144 
Duration of illness (days) – 
median (IQR) 
69
2 15 (10, 30) 
39
9 15 (10, 30) 
29
3 15 (10, 30) 0.763 
Glasgow coma score – 
median (IQR) 
69
2 15 (12, 15) 
39
9 15 (13, 15) 
29
3 14 (11, 15) 
<0.00
01 
HIV infection - Positive – 
no. (%) 
69
2 288 (41.6) 
39
9 123 (30.8) 
29
3 165 (56.3) 
<0.00
01 
Treatment arm - Standard 
arm – no. (%) 
69
2 345 (49.9) 
39
9 199 (49.9) 
29
3 146 (49.8) 1 
#
BMRC Grade – no. (%) 69
2   
39
9   
29
3   0.001 
-Grade I   266 (38.4)   162 (40.6)   104 (35.5)   
-Grade II   302 (43.6)   184 (46.1)   118 (40.3)   
-Grade III   124 (17.9)   53 (13.3)   71 (24.2)   
Other diagnostic tests 
 
 
 
 
 
 
 -CSF-Smear - Positive – no. 
(%) 
68
4 
257 (37.6) 
39
4 
69 (17.5) 
29
0 
188 (64.8) 
<0.00
01 
-CSF-MGIT culture - 
Positive – no. (%) 
68
2 281 (41.2) 
38
9 53 (13.6) 
29
3 228 (77.8) 
<0.00
01 
*Diagnostic category – no. 
(%) 
69
2   
39
9   
29
3   
<0.00
01 
-Definite TBM   397 (57.4)   104 (26.1)   293 (100)   
-Probable TBM   170 (24.6)   170 (42.6)  0 (0)  
-Possible TBM   125 (18.0)   125 (31.3)  0 (0)  
Cerebrospinal fluid - 
median (IQR)               
-Leucocytes total (x 10
3 
cells/ml) 
68
6 
115 (35, 
284) 
39
5 76 (22, 198) 
29
1 
200 (64, 
388) 
<0.00
01 
-Neutrophils (%) 
65
5 10 (0, 32) 
37
1 3 (0, 15) 
28
4 20 (5, 56) 
<0.00
01 
-Lymphocytes (%) 65 90.0 (68, 37 97.5 (85, 28 79.5 (44, 95) <0.00
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6 100) 2 100) 4 01 
-Protein (g/l) 66
6 1.2 (0.6, 1.9) 
37
9 1.0 (0.5, 1.7) 
28
7 1.4 (0.9, 2.4) 
<0.00
01 
-Glucose (mmol/l) 66
6 1.9 (1.3, 2.7) 
37
9 2.2 (1.4, 3.0) 
28
7 1.6 (1.0, 2.2) 
<0.00
01 
-Lactate (mmol/l) 63
8 4.8 (3.5, 6.5) 
35
7 4.1 (2.9, 5.6) 
28
1 5.9 (4.5, 7.4) 
<0.00
01 
All summary statistics are absolute counts (%) for categorical variables and median (inter-quartile range = IQR) for 
continuous data. n refers to the number of patients with non-missing data for the corresponding variable. 
p values are descriptive only and based on χ2 test for categorical data and Mann-Whitney test for continuous data. 
#
BMRC denotes modified British Medical Research Council criteria. Grade I indicates a GCS of 15 with no 
neurologic signs (baseline), grade II a score of 11 to 14 (or 15 with focal neurologic signs), and grade III a score of 
10 or less. 
*Diagnostic categories were assigned according to the consensus case definition.
1 
Patients with an unlikely 
diagnosis of tuberculous meningitis had a score of <6. Confirmed other diagnosis was only made based on 
microbiological evidence (Marais et al.; The Lancet Infectious diseases. 2010; 10(11): 803-12) 
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Table 2. Relationship of Mtb load and white cell numbers and cytokines in blood and CSF 
from TBM patients by Spearman correlation 
Patient 
group Blood Cerebrospinal fluid  
  
Leuco
cytes 
Lympho
cytes 
Neutro
phils 
Leuco
cytes 
Lympho
cytes 
Neutro
phils 
IL-
1β 
TNF
α PC1 PC2 
All TB, n 650 649 650 682 653 651 521 522 518 518 
r 
-0.027 0.242 -0.085 -0.273 -0.11 -0.395 -
0.523 
-0.48 -
0.493 
0.185 
p value 0.486 
< 
0.0001 
0.031 
< 
0.0001 
0.005 
< 
0.0001 
< 
0.000
1 
< 
0.000
1 
< 
0.000
1 
< 
0.000
1 
Adjusted p 
value 
0.486 
< 
0.0001 
0.062 
< 
0.0001 
0.014 
< 
0.0001 
< 
0.000
1 
< 
0.000
1 
< 
0.000
1 
< 
0.000
1 
HIV-
uninfected, 
n 
382 382 382 401 390 389 304 304 300 300 
r 
-0.116 0.24 -0.182 -0.199 -0.048 -0.342 -
0.456 
-
0.413 
-
0.448 
0.127 
p value 0.024 
< 
0.0001 
< 
0.0001 
< 
0.0001 
0.343 
< 
0.0001 
< 
0.000
1 
< 
0.000
1 
< 
0.000
1 
0.028 
Adjusted p 
value 
0.056 
< 
0.0001 
0.001 0.0003 0.343 
< 
0.0001 
< 
0.000
1 
< 
0.000
1 
< 
0.000
1 
0.056 
HIV-
infected, n 
268 267 268 281 263 262 217 218 218 218 
r 
-0.164 0.129 -0.204 -0.35 -0.206 -0.388 -
0.499 
-
0.515 
-
0.487 
0.114 
p value 0.007 0.035 0.001 
< 
0.0001 
0.001 
< 
0.0001 
< 
0.000
1 
< 
0.000
1 
< 
0.000
1 
0.092 
Adjusted p 
value 
0.021 0.070 0.003 
< 
0.0001 
0.003 
< 
0.0001 
< 
0.000
1 
< 
0.000
1 
< 
0.000
1 
0.092 
Analyses were performed by using GeneXpert Ct values and log10 -transformed cell counts, IL-1β and TNF-α 
r: Spearman’s rho correlation coefficient, in bold if adjusted p < 0.05. p values were adjusted with the Hochberg method. 
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Table 3. Association between pre-treatment variables and new neurological events and 
death by multinomial logistic regression analysis 
  
All patients (n = 
692) 
HIV-uninfected (n 
= 404)  
HIV-infected (n = 
288) 
Variables 
HR (95% 
CI) 
p 
value 
HR (95% 
CI) 
p 
value 
HR (95% 
CI) 
p 
value 
New neurological events (Mtb 
load effect)          
 
  
Mtb load (per 10-fold increase) 
1.68 (1.26-
2.25) 
0.000
4 
2.02 (1.26-
3.23) 0.003 
0.67 (0.16-
0.98) 0.038 
Mtb below LOD 
3.12 (0.96-
10.1) 0.057 
6.83 (1.10-
42.4) 0.039 
1.32 (0.25-
7.03) 0.745 
New neurological events 
(adjusted effect) †             
Mtb load (per 10-fold increase) § 
1.56 (1.14-
2.11) 0.005 
1.97 (1.18-
3.28) 0.009 
1.43 (0.95-
2.15) 0.082 
Mtb below LOD 
2.84 (0.83-
9.68) 0.096 
7.60 (1.05-
54.9) 0.044 
1.55 (0.27-
8.75) 0.617 
Age (per 10-y increase)             
1.07 (0.91-
1.27) 0.416 
1.09 (0.90-
1.31) 0.367 
1.16 (0.67-
2.03) 0.593 
Weight (per 10-kg increase)         
1.14 (0.87-
1.49) 0.325 
1.04 (0.74-
1.46) 0.831 
1.33 (0.83-
2.12) 0.228 
Glasgow coma score (per point 
increase) 
0.77 (0.71-
0.84) 
< 
0.000
1 
0.77 (0.69-
0.85) 
< 
0.000
1 
0.75 (0.63-
0.89) 0.001 
CSF leukocyte count (per 10-
fold increase) 
1.00 (0.99-
1.00) 0.552 
1.00 (0.99-
1.00) 0.733 
1.00 (0.99-
1.01) 0.393 
Intensified regimen              
0.84 (0.53-
1.33) 0.453 
0.53 (0.29-
0.96) 0.037 
1.76 (0.80-
3.90) 0.159 
HIV infected 
1.07 (0.64-
1.80) 0.791 …   …   
Antiretroviral therapy at 
enrolment             …   …   
1.83 (0.80-
4.18) 0.149 
LTA4H genotype: CC vs TT 
1.08 (0.51-
2.28) 0.830 
1.36 (0.49-
3.77) 0.547 
0.65 (0.20-
2.10) 0.473 
LTA4H genotype: CT vs TT 
0.96 (0.46-
2.02) 0.915 
0.84 (0.30-
2.34) 0.741 
0.9 (0.28-
2.86) 0.856 
Mortality (Mtb load effect)           
 
  
Mtb load (per 10-fold increase) 
1.49 (1.15-
1.92) 0.002 
1.54 (0.96-
2.48) 0.072 
0.73 (0.54-
0.99) 0.045 
Mtb below LOD 
3.06 (1.14-
8.22) 0.026 
3.82 (0.66-
22.1) 0.134 
3.22 (0.94-
11.05) 0.063 
Mortality (adjusted effect)              
Mtb load (per 10-fold increase) ¶ 
1.25 (0.94-
1.68) 0.127 
1.43 (0.82-
2.50) 0.207 
1.14 (0.79-
1.64) 0.480 
Mtb below LOD 
2.76 (0.89-
8.53) 0.077 
2.72 (0.35-
21.3) 0.341 
2.45 (0.58-
10.2) 0.220 
Age (per 10-y increase)             1.52 (1.30- < 1.68 (1.40- < 0.91 (0.59- 0.675 
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1.78) 0.000
1 
2.01) 0.000
1 
1.41) 
Weight (per 10-kg increase)         
0.67 (0.51-
0.88) 0.003 
0.87 (0.59-
1.27) 0.475 
0.58 (0.39-
0.88) 0.010 
Glasgow coma score (per point 
increase) 
0.69 (0.64-
0.75) 
< 
0.000
1 
0.71 (0.64-
0.80) 
< 
0.000
1 
0.65 (0.56-
0.75) 
< 
0.000
1 
CSF leukocyte count (per 10-
fold increase) 
1.00 (0.99-
1.00) 0.270 
0.98 (0.97-
1.00) 0.094 
1.00 (0.99-
1.00) 0.933 
Intensified regimen              
0.91 (0.60-
1.38) 0.667 
0.77 (0.42-
1.41) 0.405 
1.15 (0.64-
2.08) 0.637 
HIV infected 5.50 (3.38-
8.96) 
< 
0.000
1 …   …   
Antiretroviral therapy at 
enrolment             …   …   
0.80 (0.43-
1.50) 0.487 
LTA4H genotype: CC vs TT 
2.24 (1.06-
4.76) 0.033 
3.82 (1.02-
14.3) 0.046 
1.66 (0.64-
4.35) 0.297 
LTA4H genotype: CT vs TT 
1.86 (0.87-
3.96) 0.108 
2.04 (0.54-
7.65) 0.289 
1.83 (0.69-
4.87) 0.225 
 
Abbreviation: HIV, Human Immunodeficiency Virus; CI, confidence interval; CSF, cerebrospinal fluid; HR, hazard ratio; LOD, 
limit of detection 
Mtb load below LOD if GeneXpert was negative. Mtb load covariate and indicator of LOD were used in the model.  
† Adjusted effect means adjusted for risk factors in the multivariate model. 
§ p values adjusted by the Hochberg method for association of Mtb load and new neurological events: p = 0.045 (all patients), p = 
0.075 (HIV-uninfected), p = 0.823 (HIV-infected). 
¶ p values adjusted by the Hochberg method for association of Mtb load and death: p = 0.382 (all patients), p = 0.475 (HIV-
uninfected), p = 0.933 (HIV-infected). 
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